The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma
International Journal of Molecular Sciences · 19.03.2026 · 27 (6) · 2781
DOI: 10.3390/ijms27062781 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.03.2026. Verfasst von Sara M Steinmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Heat Shock Transcription Factors, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: internal funding from the Institute of Pathology, University of Regensburg.
Abstract (Originalsprache)
Heat-shock factor 1 (HSF1) is a multifunctional transcription factor whose overexpression is associated with the development, progression, and aggressiveness of several tumor types, including hepatocellular carcinoma (HCC). In the present study, we thoroughly investigated the antitumor activity of NXP800, a recently developed HSF1 inhibitor that is currently tested in clinical trials, on HCC growth. We discovered that NXP800 inhibits the cell growth of human HCC cell lines by reducing proliferation, inducing apoptosis, and causing DNA damage. At the metabolic level, NXP800 significantly decreased mitochondrial respiration, which was associated with extensive structural alterations in the mitochondria, and reduced glycolysis of HCC cells. At the molecular level, NXP800 administration led to the upregulation of the integrated stress response and downregulation of the E2F1 signaling cascade. In addition, NXP800 profoundly constrained the growth of HCC patient-derived organoids. Furthermore, NXP800 antitumor properties were significantly augmented when NXP800 was coupled with the DNA-damaging agent doxorubicin or the PARP inhibitor olaparib. Our investigation indicates that NXP800 has significant antitumor activity and might represent a promising therapeutic agent for the treatment of human HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
- Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Italy.
- IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, 4001 Basel, Switzerland.
- Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy.
ORCID-Profile: Sara M Steinmann, Antonio Cigliano, Grazia Galleri
Förderung
- internal funding from the Institute of Pathology, University of Regensburg
Zitieren
APA
Steinmann, S. M., Lazzari, M., Kleinle, A., Pischedda, D., Cigliano, A., Galleri, G., Siegmund, H., Fischer, C., Piscuoglio, S., Evert, M., & Calvisi, D. F. (2026). The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 27(6), 2781. https://doi.org/10.3390/ijms27062781
Vancouver
Steinmann SM, Lazzari M, Kleinle A, Pischedda D, Cigliano A, Galleri G, et al. The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2026;27(6):2781. doi:10.3390/ijms27062781
BibTeX
@article{Steinmann2026,
author = {Steinmann, Sara M and Lazzari, Melania and Kleinle, Augustinus and Pischedda, Dora and Cigliano, Antonio and Galleri, Grazia and Siegmund, Heiko and Fischer, Claudia and Piscuoglio, Salvatore and Evert, Matthias and Calvisi, Diego F},
title = {The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2781},
doi = {10.3390/ijms27062781}
}
EUVIMED